Brief: PharmAbcine Announces First Patient Dosed In nAMD Phase I Trial
26/07/2023 13:23
July 26 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE ANNOUNCES FIRST PATIENT DOSED IN THE PHASE I
CLINICAL TRIAL OF ITS NOVEL TIE2 AGONISTIC ANTIBODY IN NAMD
Source text for Eikon: ID:nPn24MlQ0a
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration